The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation
Reilly, Christopher Raja, Anandavelu Anilkumar, Pillai Sullivan, Julie White, Lisa Bahron, Ali Marsh, Julie Mansur, Adel H
Reilly, Christopher
Raja, Anandavelu
Anilkumar, Pillai
Sullivan, Julie
White, Lisa
Bahron, Ali
Marsh, Julie
Mansur, Adel H
Abstract
a total of 66 patients initiated on mepolizumab with a median follow-up of 45.8 (42.4,48.1) months were included in the study [mean age 50.3 years (range 18-79), females 50 (73%) ]. At 20.7 months of treatment, 42 patients (63.6%) had positive response, 13 (19.7%) negative response, and 11 (16.7%) discontinued due to other factors. At 45.8 months, 35 (53%) patients were still on mepolizumab, 21 (31.8%) switched to a different biologic, and 10 (15.2%) discontinued biologics. Two deaths were recorded during the study period.The median blood eosinophil was reduced from 0.43x109/L (0.27, 0.75) to 0.04 (0.0, 0.1) (p < 0.00001)]. The median annual exacerbations were reduced from 6.0 (4,8) to 1.0 (0.0,3.0) (p < 0.00001), and mOCS use was reduced from59% to 29%, p = 0.001. The mean asthma control questionnaire-6 (ACQ6) improved from 3.1 ± 1.7 to 2.1 ± 1.3 (p < 0.00001).
Citations
Altmetric:
Date
2023-12-13
Type
Article
Subject
Respiratory medicine
Collections
Citation
Reilly C, Raja A, Anilkumar P, Sullivan J, White L, Bahron A, Marsh J, Mansur AH. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation. J Asthma. 2024 Jun;61(6):561-573. doi: 10.1080/02770903.2023.2294908.
Journal / Source Title
Journal of Asthma
DOI
10.1080/02770903.2023.2294908
PMID
38088937
Publisher
Informa Healthcare